WRD is interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Inflammatory Bowel Disease
- Psoriasis
- Multiple Sclerosis and other mechanistically related smaller indications with high unmet need
Specific areas of interest include:
- Cytokines and their signaling pathways
- Adaptive Immunity, Lymphocyte biology including Th17 lymphocytes
- Regulatory cells and Tolerance induction
- Technology platforms and products to help understand patient segmentation in the disease areas of interest and develop precision medicine strategies for innovative portfolio products
Not actively seeking partnering opportunities in:
- Adequately controlled RA
- TNFα, IL-1β targeting biologics
- B cell depleting biologics
- Corticosteroids
